Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03498521
Title A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

Advanced Solid Tumor

Therapies

Atezolizumab + Paclitaxel

Carboplatin

Carboplatin + Paclitaxel

Olaparib

Vismodegib

Alectinib

Bevacizumab + Erlotinib

Cisplatin + Gemcitabine

Cobimetinib + Vemurafenib

Ipatasertib + Paclitaxel

Cisplatin + Paclitaxel

Gemcitabine

Atezolizumab

Entrectinib

Pertuzumab + Trastuzumab

Paclitaxel + Pertuzumab + Trastuzumab

Ipatasertib

Carboplatin + Gemcitabine

Age Groups: adult | senior
Covered Countries


No variant requirements are available.